

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Bioniche Therapeutics Limited	05/19/2006
RECEIVING PARTY DATA	
Name:	Bioniche Teoranta
Street Address:	Unit 6, Casla Industrial Estate
City:	Casla, County Galway
State/Country:	IRELAND
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	5880108
Patent Number:	5888986
Patent Number:	5591724
Patent Number:	6667296
Application Number:	10705255
CORRESPONDENCE DATA	
Fax Number:	(404)541-3160
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	404 815 6500
Email:	mcogburn@kilstock.com
Correspondent Name:	John S. Pratt, Kilpatrick Stockton
Address Line 1:	1100 Peachtree Street
Address Line 2:	Suite 2800
Address Line 4:	Atlanta, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	42368/330871
NAME OF SUBMITTER:	Margaret A. Cogburn

OP \$200.00 5880108

500296629

PATENT  
REEL: 019432 FRAME: 0160

**Total Attachments: 6**

source=Scanned U.S. assignment - BTL to BT#page1.tif

source=Scanned U.S. assignment - BTL to BT#page2.tif

source=Scanned U.S. assignment - BTL to BT#page3.tif

source=Scanned U.S. assignment - BTL to BT#page4.tif

source=Scanned U.S. assignment - BTL to BT#page5.tif

source=Scanned U.S. assignment - BTL to BT#page6.tif

**PATENT**

**REEL: 019432 FRAME: 0161**

## **PATENT ASSIGNMENT**

**THIS PATENT ASSIGNMENT** (this "Assignment") is made and entered into as of MAY 19, 2006 ("Effective Date") by and between **BIONICHE THERAPEUTICS LIMITED**, an Ontario corporation, with its principal office at 231 Dundas Street East, Belleville, Ontario K8N 1E2, Canada ("Assignor"), and **BIONICHE TEORANTA**, a limited company organized in the Republic of Ireland, Unit 6, Casla Industrial Estate, Casla, County Galway, Ireland ("Assignee").

**WHEREAS**, Assignor and Assignee are parties to that certain Purchase Agreement dated May 2, 2006 (the "Agreement"), pursuant to which Assignor has agreed to sell and Assignee has agreed to purchase the assets, properties and rights pertaining to the Business as defined in the Agreement;

**WHEREAS**, Assignor is the sole and exclusive owner of the entire right, title and interest in, to and under those United States patents and patent applications identified and set forth on Schedule A and the foreign patents and patent applications identified and set forth on Schedule B (the "Patents"); and

**WHEREAS**, Assignee wishes to acquire and Assignor wishes to assign all right, title and interest in and to the Patents.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, transfer and set over to Assignee, the entire right, title and interest in and to the Patents, for the United States and for all foreign countries, including any continuations, divisions, continuations-in-part, reissues, reexaminations, extensions or foreign equivalents thereof, and including the subject matter of all claims which may be obtained therefrom for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patents, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Assignor authorizes and requests the Commissioner of Patents and Trademarks to record Assignee as owner of the Patents, including any continuations, divisions, continuations-in-part, reissues, reexaminations or extensions thereof, and to issue any and all letters patent of the United States thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.


Assignor shall, at Assignee's expense, provide Assignee, its successors, assigns or other legal representatives, cooperation and assistance at Assignee's request and expense (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation as may be reasonably required): (1) in

the preparation and prosecution of any applications covering the inventions assigned herein; (2) in the prosecution or defense of any interference, opposition, reexamination, reissue, infringement or other proceedings that may arise in connection with any of the patent rights assigned herein, including, but not limited to, testifying as to any facts relating to the patent rights assigned herein and this Assignment; (3) in obtaining any additional patent protection that Assignee may deem appropriate which may be secured under the laws now or hereafter in effect in the United States or any other country; and (4) in the implementation or perfection of this Assignment.

\* \* \* \* \*

**IN WITNESS WHEREOF**, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.


**BIONICHE THERAPEUTICS LIMITED**



Name: Graeme McRae

Title: President

**BIONICHE TEORANTA**



Name: David J. Koo

Title: Director

## **SCHEDULE A**

### **U.S. PATENTS AND PATENT APPLICATIONS**

<b>Title</b>	<b>Country</b>	<b>Patent No. Issue Date</b>	<b>Pub. No./ Pub. Date</b>	<b>Applic. No./ Filing Date</b>
Method for treating the internal urinary bladder and associated structures using hyaluronic acid	U.S.	5,880,108 3/9/1999		08/824,890 3/26/1997
Method for treating the urinary bladder and associated structures using hyaluronic acid	U.S.	5,888,986 3/30/1999		08/644,438 5/13/1996
	U.S.			08/591,015 2/8/1996
Method for treating the urinary bladder and associated structures using hyaluronic acid	U.S.	5,591,724 1/7/1997		08/388,038 2/14/1995
Method for preventing and reducing radiation cystitis using hyaluronic acid	U.S.	6,667,296 12/23/2003		09/830,063 7/30/2001
Method for preventing, reducing, and treating radiating cystitis using hyaluronic acid	U.S.		2004 0152662 8/5/2004	10/705,255 11/10/2003

## SCHEDULE B

### FOREIGN PATENTS AND PATENT APPLICATIONS

Title	Country	Patent No. Issue Date	Pub. No./ Pub. Date	Applic. No./ Filing Date
Use of hyaluronic acid for the treatment of interstitial cystitis	Australia	705289 5/20/1999		46179/96 2/14/1996
A method for preventing, reducing and treating radiating cystitis using hyaluronic acid	Australia	761158 5/29/2003		64558 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	Brazil			9607601 2/14/1996
Use of hyaluronic acid for the treatment of interstitial cystitis	Canada	2203621 4/28/1998		2203621 2/14/1996
A method for preventing, reducing and treating radiating cystitis using hyaluronic acid	Canada		2347110 5/4/2000	2347110 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	China		CN1181016A 5/6/1998	96192529 2/14/1996
Use of hyaluronic acid for the treatment of interstitial cystitis	Czech Republic	288218 5/16/2001		972574 2/14/1996
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Austria	247476 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Austria	761158 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Belgium	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Belgium	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Denmark	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Denmark	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP France	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP France	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Germany	69629553 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Germany	69916643 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Great Britain	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Great Britain	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Greece	3046731 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Greece	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Ireland	EP 813417 8/20/2003		EP 96901681 2/14/1996

Title	Country	Patent No. Issue Date	Pub. No./ Pub. Date	Applic. No./ Filing Date
Use of hyaluronic acid for the treatment of radiation cystitis	EP Ireland	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Italy	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Italy	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Liechtenstein validated under Switzerland	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Liechtenstein validated under Switzerland	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Luxembourg	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Luxembourg	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Monaco	204144 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Monaco	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Netherlands	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Netherlands	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Portugal	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Portugal	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Spain	2205013 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Spain	2219070 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Sweden	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Sweden	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EP Switzerland	EP 813417 8/20/2003		EP 96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EP Switzerland	EP 1124546 4/21/2004		EP 99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	EPO	813417 8/20/2003		96901681 2/14/1996
Use of hyaluronic acid for the treatment of radiation cystitis	EPO	1124546 4/21/2004		99952186.7 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	Hungary		9800467 6/29/1998	989800467 2/14/1996
Use of hyaluronic acid for the treatment of interstitial cystitis	India	181358 6/4/1999	181358 5/30/1998	96CA262 2/13/1996
Use of hyaluronic acid for the treatment of interstitial cystitis	Indonesia	P-961251 4/8/2003		0.010.305 5/13/1996

<b>Title</b>	<b>Country</b>	<b>Patent No. Issue Date</b>	<b>Pub. No./ Pub. Date</b>	<b>Applic. No./ Filing Date</b>
Use of hyaluronic acid for the treatment of interstitial cystitis	Japan		10513476 12/22/1998	96524545 2/14/1996
A method for preventing, reducing and treating radiating cystitis using hyaluronic acid	Japan			2000 577997 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	Korea	268660 10/16/2000		97705648 8/14/1997
Use of hyaluronic acid for the treatment of interstitial cystitis	Mexico	204144 9/10/2001		
Use of hyaluronic acid for the treatment of interstitial cystitis	New Zealand	300903 7/29/1999		300903 2/14/1996
A method for preventing, reducing and treating radiating cystitis using hyaluronic acid	New Zealand	511068 10/31/2003		511068 10/22/1999
Use of hyaluronic acid for the treatment of interstitial cystitis	Norway	315842 11/3/2003		973732 8/13/1997
Use of hyaluronic acid for the treatment of interstitial cystitis	Romania			9701531 8/13/1997
Use of hyaluronic acid for the treatment of interstitial cystitis	Taiwan	149551 5/21/2002		85108618 7/16/1996
Use of hyaluronic acid for the treatment of interstitial cystitis	Turkey			9700782 2/14/1996